Orthocell Ltd
Orthocell Limited is an Australia-based regenerative medicine company.
The business
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Small Caps Research
No research on Orthocell Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise OCC based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Orthocell Appoints First Canadian Distributor For Remplir Collagen Nerve Wrap
Orthocell (ASX: OCC) has appointed the first Canadian distributor for its innovative Remplir collagen nerve wrap ahead of an official in-country launch next month. The undisclosed distributor reportedly has a wealth of expertise in the nerve, spine, and orthopaedic implant markets, with established links in the nation’s healthcare sector to drive product adoption. Orthocell has secured […]
Orthocell’s Remplir Used by Australian Urologists in Prostate Cancer Surgery
Regenerative medicine company Orthocell (ASX: OCC) has introduced its flagship nerve repair device Remplir to Australian urologists for use in nerve-sparing robotic-assisted radical prostatectomies (RARP). Currently up to 80% of men experience erectile dysfunction and up to 35% suffer from urinary incontinence after radical prostatectomy due to damage of the peripheral nerves in the neurovascular […]
Orthocell Posts Record Full-Year Revenue, Takes Remplir and Striate into New Global Markets
Regenerative medicine company Orthocell (ASX: OCC) has reported a record revenue of $9.19 million for the 12 months to the end of June 2025, underscoring market penetration and sales growth of its flagship nerve repair product Remplir in Australia. The figure was up 35.8% on the previous financial year — boosted by $2.73m revenue in […]
Orthocell’s Remplir nerve repair technology sees first surgical use in US procedure
Regenerative medicine company Orthocell (ASX: OCC) has achieved a major breakthrough in the global development of its Remplir technology with the successful completion of a first surgery in the US. Doctors at a hospital in Ohio used the company’s trademarked nerve repair product in a surgical procedure to repair a foot injury. Remplir, developed for […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.